Literature DB >> 27652378

A Journey in Science: The Privilege of Exploring the Brain and the Immune System.

Lawrence Steinman1.   

Abstract

Real innovations in medicine and science are historic and singular; the stories behind each occurrence are precious. At Molecular Medicine we have established the Anthony Cerami Award in Translational Medicine to document and preserve these histories. The monographs recount the seminal events as told in the voice of the original investigators who provided the crucial early insight. These essays capture the essence of discovery, chronicling the birth of ideas that created new fields of research; and launched trajectories that persisted and ultimately influenced how disease is prevented, diagnosed, and treated. In this volume, the Cerami Award Monograph is by Lawrence Steinman, MD, of Stanford University in California. A visionary in the field of neurology, this is the story of Dr. Steinman's scientific journey.

Keywords:  immunology; molecular biology; neuroimmune; neurology; pediatric neurology

Mesh:

Year:  2016        PMID: 27652378      PMCID: PMC5004718          DOI: 10.2119/molmed.2015.00263

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  98 in total

Review 1.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Authors:  Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

2.  Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment.

Authors:  S Brocke; C Piercy; L Steinman; I L Weissman; T Veromaa
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

3.  Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein.

Authors:  S Brocke; K Gijbels; M Allegretta; I Ferber; C Piercy; T Blankenstein; R Martin; U Utz; N Karin; D Mitchell; T Veromaa; A Waisman; A Gaur; P Conlon; N Ling; P J Fairchild; D C Wraith; A O'Garra; C G Fathman; L Steinman
Journal:  Nature       Date:  1996-01-25       Impact factor: 49.962

4.  Isolation of cDNA clones encoding T cell-specific membrane-associated proteins.

Authors:  S M Hedrick; D I Cohen; E A Nielsen; M M Davis
Journal:  Nature       Date:  1984 Mar 8-14       Impact factor: 49.962

5.  Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein.

Authors:  A Ben-Nun; H Wekerle; I R Cohen
Journal:  Nature       Date:  1981-07-02       Impact factor: 49.962

6.  Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2.

Authors:  Syed Sohail Ahmed; Wayne Volkmuth; José Duca; Lorenzo Corti; Michele Pallaoro; Alfredo Pezzicoli; Anette Karle; Fabio Rigat; Rino Rappuoli; Vas Narasimhan; Ilkka Julkunen; Arja Vuorela; Outi Vaarala; Hanna Nohynek; Franco Laghi Pasini; Emanuele Montomoli; Claudia Trombetta; Christopher M Adams; Jonathan Rothbard; Lawrence Steinman
Journal:  Sci Transl Med       Date:  2015-07-01       Impact factor: 17.956

7.  The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

Authors:  Sawsan Youssef; Olaf Stüve; Juan C Patarroyo; Pedro J Ruiz; Jennifer L Radosevich; Eun Mi Hur; Manuel Bravo; Dennis J Mitchell; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil
Journal:  Nature       Date:  2002-11-07       Impact factor: 49.962

8.  Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity.

Authors:  Michael Platten; Sawsan Youssef; Eun Mi Hur; Peggy P Ho; May H Han; Tobias V Lanz; Lori K Phillips; Matthew J Goldstein; Roopa Bhat; Cedric S Raine; Raymond A Sobel; Lawrence Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-19       Impact factor: 11.205

9.  Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis.

Authors:  J W Lindsey; S Hodgkinson; R Mehta; R C Siegel; D J Mitchell; M Lim; C Piercy; T Tram; L Dorfman; D Enzmann
Journal:  Neurology       Date:  1994-03       Impact factor: 9.910

10.  The discovery of natalizumab, a potent therapeutic for multiple sclerosis.

Authors:  Lawrence Steinman
Journal:  J Cell Biol       Date:  2012-10-29       Impact factor: 10.539

View more
  1 in total

1.  Type II Collagen-Specific B Cells Induce Immune Tolerance in Th1-Skewed, Th2-Skewed, and Arthritis-Prone Strains of Mice.

Authors:  Shukkur M Farooq; Hossam M Ashour
Journal:  Cells       Date:  2021-04-12       Impact factor: 6.600

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.